Archived Insight | April 27, 2022

Model Pension Plan's Funded Status Rises

During the first quarter of 2022, the funded status of the model pension plan examined in each issue of Prism rose by 6 percentage points, to 107 percent, as illustrated in the graph below.

This increase in funded status is primarily attributable to a 11 percent decrease in liabilities, partially offset by a 6 percent decrease in assets.

Get the full data

Model Pension Plans Funded Status Rises Q1 2022 Download Now

Prism Review of First Quarter 2022

Aspects of investment performance that contributed to the loss in asset value

Equity and fixed income returns were negative across the board during Q1, as Russia’s invasion of Ukraine and relentlessly increasing inflation readings globally dominated headlines.

U.S. equity markets had their worst performance since Q1 2020 (when COVID-19 lockdowns began), with March providing slightly positive returns, which could not offset the negative returns during the first two months of the quarter.

Fixed income returns were poor both domestically and internationally as interest rates soared across the globe.

Examine your own DB plan’s experience

Plan sponsors should examine changes in their own DB plans’ assets, liabilities and funded ratios from the vantage point of both accounting and funding metrics.

We can help employers project their DB plans’ funded ratios with a complete view of the range of a plan’s possible future statuses, presenting early warning signs of potential challenges.

See more insights

Asian Female Pharmacist Uses Computer To Check Inventory For A Drug

Designing and Negotiating Affordable Pharmacy Benefits

Learn how health plan sponsors can improve pharmacy benefit value through PBM contracting, formulary management and clinical oversight.
Focused Business Woman Working On Laptop Computer Reading

Many Retirement Plans Must Be Amended by December 31, 2026

Learn which retirement plans must be amended by December 31, 2026 and how SECURE Act discretionary and required amendments differ.
Man Self Injecting GLP 1 Weight Loss Medication Pen At Home

GLP-1s Have Disrupted the Market for Other Diabetes Drugs

Segal’s SHAPE data shows how rising GLP-1 use coincided with declines in insulin, Metformin and DPP-4 inhibitor use.

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.